Clinical data | |
---|---|
Trade names | Carafen |
ATC code |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.000.922 |
Chemical and physical data | |
Formula | C18H27NO2 |
Molar mass | 289.419 g·mol−1 |
3D model (JSmol) | |
| |
|
Caramiphen is an anticholinergic drug used in the treatment of Parkinson's disease.[1] In combination with phenylpropanolamine it is used as a cough suppressant and nasal decongestant to treat symptoms associated with respiratory illnesses such as cold, allergies, hay fever, and sinusitis.[2] It was added to the British National Formulary in 1963, with a dosage of 10 to 20 mg. Side effects include nausea, dizziness, and drowsiness.[3]
It binds to the sigma-1 receptor with an IC50 value of 25 nM.[4]